Ab­b­Vie calls off PhI tri­al for I-Mab’s CD47 days af­ter Zai Lab shelves its own pro­gram

The CD47 field ran in­to an­oth­er hur­dle Tues­day as I-Mab qui­et­ly dis­closed in an SEC fil­ing that Ab­b­Vie is say­ing good­bye to a Phase I study of the biotech’s drug.

Weeks af­ter end­ing an ex­plorato­ry tri­al of I-Mab’s CD47 an­ti­body, Ab­b­Vie has now called it quits on an­oth­er ear­ly-stage tri­al. The Phase I was test­ing the drug, lem­zopar­limab, in com­bi­na­tion with azac­i­ti­dine and vene­to­clax in pa­tients with acute myeloid leukemia and myelodys­plas­tic syn­drome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.